Click here to visit our General Public Section

 

What is C-Reactive Protein (CRP) ? - Guidelines - Clinical Trials - Discussion Forum - Editorial Board - Supporter - About
Search for: Your source on hs-CRP testing
Your source on hs-CRP testing  Sign In      Register Now!
Online Presentations
Browse by:     topic   |   date  |   speaker  |   accredited presentations  |   podcast  
Biography
Dr. Christie Mitchell Ballantyne

Associate Chief and Professor, Section of Atherosclerosis and Lipoprotein Research, Baylor College of Medicine, Houston, TX.

Director, Center for Cardiovascular Disease Prevention
Director, The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory
Director, Clinical Activities
Co-director, Lipid Metabolism and Atherosclerosis Clinic

Basic Research
The general area of research interest for Dr. Ballantyne's laboratory is the role of inflammation and cell adhesion molecules in vascular disease. Dr. Ballantyne and colleagues have adopted a molecular genetic approach toward this problem and have utilized targeted homologous recombination to develop mutant mice deficient in various cell adhesion molecules including CD11a, CD11b, CD11c, and CD11d. These mice are being studied in models of myocardial ischemia-reperfusion injury, vascular injury and acute inflammation. The mechanisms by which hyperlipidemia and obesity influence inflammation are also being studied. Characterization of the mutant mice involves a wide range of techniques, including molecular biology, cell biology, and integrative physiology.

Clinical Research
Dr. Ballantyne's clinical research is the prevention of atherosclerotic vascular disease. This interest includes pharmacological studies to assess the efficacy and benefits of lipid-lowering drug therapy including trials which utilize ultrasound and MRI to examine the effects of lipid-lowering drugs on the progression of atherosclerosis. As the Director of The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory, which serves as the core laboratory for the Atherosclerosis Risk in Communities (ARIC) study, Dr. Ballantyne is studying whether novel biomarkers might be useful in identifying individuals at high risk for cardiovascular disease, the metabolic syndrome and diabetes. Both genomics and proteomics are being used to identify novel molecules that are increased with atherosclerosis and the metabolic syndrome.

Presentations by Dr. Christie Mitchell Ballantyne that are available on CRPhealth.com
C-Reactive Protein and Lipid-Lowering Therapy
2004-07-09


 Your source on CRP information
CRPhealth.com is owned by E-MedHosting.com Inc. Last update: 2010-07-21
Copyright © 2000-2010 E-MedHosting.com inc. All rights reserved.
Disclaimer  |  Sponsors' Disclaimer  |  Help / Contact us